 Glatiramer Acetate
"Glatiramer Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068717
|
| MeSH Number(s) |
D12.644.219
|
| Concept/Terms |
TV 5010- TV 5010
- 5010, TV
- TV5010
- TV-5010
|
Below are MeSH descriptors whose meaning is more general than "Glatiramer Acetate".
Below are MeSH descriptors whose meaning is more specific than "Glatiramer Acetate".
This graph shows the total number of publications written about "Glatiramer Acetate" by people in this website by year, and whether "Glatiramer Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glatiramer Acetate" by people in Profiles.
-
Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019 Jun; 25(3):715-735.
-
Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732.
-
Kuerten S, Jackson LJ, Kaye J, Vollmer TL. Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis. CNS Drugs. 2018 11; 32(11):1039-1051.
-
Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL. CD40-Mediated NF-?B Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. J Immunol. 2016 12 01; 197(11):4257-4265.
-
Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan; 15(1):35-46.
-
Zhang CJ, Zhai H, Yan Y, Hao J, Li MS, Jin WN, Su N, Vollmer TL, Shi FD. Glatiramer acetate ameliorates experimental autoimmune neuritis. Immunol Cell Biol. 2014 Feb; 92(2):164-9.
-
Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr; 19(4):278-85.
-
Bomprezzi R, Schaefer R, Reese V, Misra A, Vollmer TL, Kala M. Glatiramer acetate-specific antibody titres in patients with relapsing?/?remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. Scand J Immunol. 2011 Sep; 74(3):219-226.
-
Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98.
-
Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol. 2011 Jun; 235(1-2):9-17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|